Vaccibody AS will be registered on the NOTC-list as of January 27, 2020...
Call for extraordinary general meeting 20 December 2019...
VACCIBODY ANNOUNCES INITIAL POSITIVE CLINICAL RESPONSES WITH VB10.NEO NEOANTIGEN CANCER VACCINE...
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host its capital markets day on November 12 and is pleased to invite investors, analysts and press to presentations by the members of the company’s executive management...
SIRI TORHAUG, MD APPOINTED AS NEW CHIEF MEDICAL OFFICER...
Call for extraordinary general meeting...
VACCIBODY WILL PRESENT PRELIMINARY SAFETY, EFFICACY AND IMMUNOGENICITY RESULTS FROM ITS PHASE 1/2A (DIRECT-01) STUDY OF CANCER NEOANTIGEN VACCINE VB10.NEO IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS...
VACCIBODY ANNOUNCES MARTIN BONDE TO STEP DOWN AS CHIEF EXECUTIVE OFFICER, MICHAEL ENGSIG TO TAKE OVER...
VACCIBODY APPOINTS MICHAEL ENGSIG AS CHIEF OPERATING OFFICER...
Vaccibody - Quarterly report 2019 Q2...